Data from the much-anticipated SUMMIT study failed to show that Relvar/Breo Ellipta (fluticasone furoate/vilanterol) statistically significantly extended the lives of chronic obstructive pulmonary disease (COPD) patients, indicating to investors that the product, dubbed the "son of Advair" likely won't be restoring Glaxosmithkline plc's respiratory disease franchise to its once-great heights.